GlobeNewswire·May 8, 2026, 8:30 AM ET

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

BLA completion for HR BCG-unresponsive NMIBC is expected in the fourth quarter of 2026 following FDA alignment discussions.
PIVOT-006 Phase 3 topline data for cretostimogene monotherapy in intermediate-risk NMIBC is anticipated in the first half of 2026.
CORE-008 Cohort CX Phase 2 first results for the combination of cretostimogene & gemcitabine in high-risk NMIBC will be presented at AUA 2026 on May 16.
The company holds approximately $1.1 billion in cash, cash equivalents & marketable securities, sufficient to fund operations through 2029.
Jim DeTore was appointed Chief Financial Officer in April 2026, bringing over 30 years of life sciences leadership experience.
Q1 2026 Research & Development expenses were $43.7 million, up from $27.5 million in the prior year period due to increased clinical trial & compensation costs.
Q1 2026 General & Administrative expenses were $20.8 million, up from $14.8 million in the prior year period due to higher personnel & professional fees.
The company reported a net loss of $60.2 million ($0.71 per share) for Q1 2026 compared to $34.5 million ($0.45 per share) in the prior year.
Cash balance increased to $1.076 billion as of March 31, 2026, following the sale of 6,941,407 shares via the at-the-market facility for approximately $391.4 million.
Additional 2026 milestones include durability data for BOND-003 Cohorts C & P & CORE-008 Cohort A, & completion of the BLA submission for the initial HR BCG-unresponsive NMIBC indication.